Britain and America have forged a key bilateral deal that will ensure zero import taxes on UK medicine shipments being sold in the US market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to raise spending on pharmaceuticals through the National Health Service (NHS). This pledge ensures that duties on these crucial exports will stay at nothing for a period of the next three years.
This development comes after previous warnings to significantly raise import taxes on branded pharmaceutical imports, with increases discussed reaching double the cost.
"This deal between the UK reinforces the worldwide climate for new treatments and introduces much-needed equity to American-British drug exports," a release declared.
Trade Significance
Drugs represent one of the the United Kingdom's biggest goods shipped to the United States, which is clearly the primary destination for large companies like GSK and AstraZeneca.
Trade data show that in the one-year period to the end of last September, the UK exported pharmaceutical products worth billions to the US. This figure accounted for 17.4% of total UK exports in that timeframe.
"This guarantee protects employment, boosts funding and facilitates the UK to become a global hub for biotech and pharma," a minister commented.
Specific UK Commitments
The pact entails several specific commitments from the British government:
- Higher Cost Ceiling: The UK will raise the price threshold at which it deems new medicines to be too expensive by twenty-five percent.
- Increased NHS Spending: There is a goal to double overall health service expenditure on drugs from 0.3 percent of GDP to 0.6% over the coming ten years.
- Payback Limit: The percentage manufacturers must refund to the NHS to prevent overspending will be limited at fifteen percent. In the past, rebates exceeded twenty percent.
Recent Tensions
The pact takes place against a long-running tension between the sector and the ministers over medicine costs and NHS adoption.
The disagreement were exacerbated by assertions that American patients were paying significantly more for the equivalent treatments than patients in the UK and Europe.
Recently, several major pharmaceutical investments in the UK have been paused or abandoned, while substantial investments have been directed toward US facilities.
One official stated that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had decreased as a percentage of its total funding over the previous ten-year period.